Appointment of PMPRB chair offers opportunity for meaningful stakeholder engagement
Ottawa, ON – Innovative Medicines Canada (IMC) welcomes the new leadership of the Patented Medicine Prices Review Board (PMPRB) with […]
Patented Medicine Prices Review Board (PMPRB)
Ensuring Canada remains an attractive destination for pharmaceutical innovation.
The Patented Medicine Prices Review Board (PMPRB) ensures patented medicines sold in Canada are not excessively priced. IMC has highlighted how changes to the PMPRB affect patient access to medicines and Canada’s attractiveness for future pharmaceutical innovation.
News
Major hurdles confront Canada’s Biomanufacturing and Life Sciences Strategy
This article originally appeared in Research Money on January 25, 2023. A dwindling workforce, inefficient regulations, and lack of much-needed […]
PMPRB Delay
an Opportunity for Meaningful Consultation
Ottawa, ON – Innovative Medicines Canada (IMC) welcomes the Patented Medicine Prices Review Board (PMPRB) announcement to delay the implementation […]
Government Submissions
The Suspension and Reformulation of the PMPRB Guidelines is Urgently Required: IMC Response to PMPRB 2022 Guidelines Proposals
Innovative Medicines Canada has submitted formal feedback to the Patented Medicine Prices Review Board’s (PMPRB) revised Draft Guidelines public consultation, calling for a suspension of the planned implementation to ensure meaningful stakeholder consultation and a thorough impact analysis.
PMPRB Notice and Comment Response
Innovative Medicines Canada opposes a July 15, 2021 proposal to change international price tests for existing medicines and their line extensions from the highest of the international schedule to the median.
Proposed Guidelines Monitoring and Evaluation Plan
This submission responds to PMPRB’s consultation on its proposed Guideline Monitoring and Evaluation Plan GMEP, deeming it premature.
Policy Positions
IMC Response to PMPRB Interim Approach Consultation
IMC’s members continue to have significant concerns regarding changes to the PMPRB and future Guidelines that will implement the revised schedule of international reference countries.
PMPRB Guidelines Notice and Comment
IMC opposes a January 15, 2021 proposal to redefine ‘gap’ medicines and change the timeline for compliance – which halves the transition period to six months.
IMC Response to PMPRB 2020 Draft Guidelines
IMC critiques the June 2020 Federal Court decision that confidential third-party payments are ultra vires the Patent Act.
Letters
Letter to The Honourable Jean-Yves Duclos, P.C., M.P.
IMC calls for a suspension of the Patented Medicine Prices Review Board’s (PMPRB) guidelines consultation process.
Letter to The Hon. Chrystia Freeland, P.C., M.P.
IMC calls for a suspension of the Patented Medicine Prices Review Board’s (PMPRB) guidelines consultation process.
*Cette lettre est disponible en anglais seulement.
Letter to The Honourable Mary Ng, P.C., M.P.
IMC calls for a suspension of the Patented Medicine Prices Review Board’s (PMPRB) guidelines consultation process.
*Cette lettre est disponible en anglais seulement.
Newsroom
Breaking down and analyzing current events in the healthcare industry for our members, policy influencers and the Canadian public.
About
Our member companies, which range from fledgling start-ups to established organizations, are revolutionizing healthcare through the discovery and development of […]
